Beatriz Pascual-Anton

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.

Journal: The pharmacogenomics journal

Published: February 19, 2026

Change in MMR status as a mechanism of acquired resistance to immunotherapy in a dMMR colorectal cancer.

Change in MMR status as a mechanism of acquired resistance to immunotherapy in a dMMR colorectal cancer.

Journal: BMJ case reports

Published: December 31, 2025

Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors.

Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors.

Journal: Biomedicines

Published: July 22, 2025

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 06, 2025

Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.

Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.

Journal: British journal of cancer

Published: October 07, 2024

Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.

Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.

Journal: The oncologist

Published: June 03, 2024

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

Journal: Nature communications

Published: February 08, 2024

Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.

Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 16, 2023

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

Journal: Endocrine reviews

Published: November 30, 2022

MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms.

MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms.

Journal: Molecular oncology

Published: July 27, 2022

Correction to: Chemotherapy in NEN: still has a role?

Correction to: Chemotherapy in NEN: still has a role?

Journal: Reviews in endocrine & metabolic disorders

Published: July 01, 2022

Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?

Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?

Journal: Cancers

Published: March 01, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026